Vaccines Against Respiratory Syncytial Virus: The Time Has Finally Come

By Barney S. Graham. 2016

91 citations recorded by the source corpus.

Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality.

Subfields: Epidemiology, Infectious Diseases

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. F. Sallusto
2. A. Lanzavecchia
3. D. Veesler

In Infectious Diseases

1. David Baker
2. D. Veesler

Citations in the corpus

• Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus (2019, background): “We note that one limitation of RSV-naive animal models is that prior RSV infection is universal among adult humans, and a vaccine will presumably work in part by boosting pre-existing immunity (Graham, 2016).”